Skip to main content

Dr. John F. Dipersio, MD

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
46
In the NPI registry since
2006
Medicare patients seen, 2024
346

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1980Medical school: University of Rochester School of Medicine and Dentistry
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    MO license 105204

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
346
Services billed
37,097
Patients’ average age
69
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, pembrolizumab, 1 mg8,20015
Injection, fosaprepitant, 1 mg7,65022
Injection, azacitidine, 1 mg3,40012
Injection, denosumab, 1 mg1,92011
Injection, dexamethasone sodium phosphate, 1 mg1,16048
Injection, palonosetron hcl, 25 mcg70034
Established patient office or other outpatient visit, 30-39 minutes342127
Injection, granisetron hydrochloride, 100 mcg34019
Injection, ondansetron hydrochloride, per 1 mg30411
Insertion of needle into vein for collection of blood sample300117

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 3 companies reported 8 payments worth $6,098 in total to this clinician.

By company
Geron Corporation$3,380
Janssen Scientific Affairs, LLC$2,664
Pfizer Inc.$54.04
By type
Consulting Fee$5,428
Travel and Lodging$363
Food and Beverage$307

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Dec 11, 2025Geron Corporation
Dec 11, 2025
Consulting Fee
IMETELSTAT · HEMATOLOGY
$2,925
Sep 23, 2025Janssen Scientific Affairs, LLC
Sep 23, 2025
Consulting Fee$2,503
Dec 5, 2025Geron Corporation
Dec 5, 2025
Travel and Lodging
IMETELSTAT · HEMATOLOGY · travel to ORLANDO, FL
$363

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Missouri →

Industry-funded research

Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $214,008 in research payments for these studies, mostly to the institutions running them.

  • A phase 1/2, open-label, dose-escalation and dose-expansion cohort study of SNDX-5613 in patients with relapsed/refractory leukemias, including those harboring an mll/KMT2A gene rearrangement or nucleophosmin 1 (NPM1)…
    Syndax Pharmaceuticals, Inc.
  • Expanded access program FORSNDX-5613IN patients with relapsed/refractory acute leukemias with genetic alterations associated with hoxa overexpression
    Syndax Pharmaceuticals, Inc.
  • TAK-012-1501
    Takeda Pharmaceuticals U.S.A., Inc.
  • A phase 1, open-label, dose-escalation, and dose-expansion study to evaluate safety, tolerability, and clinical activity OFSNDX-5613IN combination with intensive chemotherapy in participants with newly diagnosed acute…
    Syndax Pharmaceuticals, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Saint Louis

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 17, 2025), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1730106295. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.